French biotech firm NicOx (Euronext Paris: COX) has entered into a research collaboration with Northern Ireland-based Re-Vana Therapeutics, an ocular pharmaceutical and drug delivery company.
The companies will explore combining NicOx' next generation of stand-alone nitric oxide (NO)-donors with Re-Vana's EyeLief long-acting photo-crosslinked biodegradable drug delivery platform for the reduction of intraocular pressure (IOP), a key risk factor for the development and progression of glaucoma.
NicOx shares were down 1.36% at 8.78 euros last morning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze